Anti-infectives in Drug Delivery—Overcoming the Gram-Negative Bacterial Cell Envelope

Chapter
First Online:
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 398)

Abstract

Infectious diseases are becoming a major menace to the state of health worldwide, with difficulties in effective treatment especially of nosocomial infections caused by Gram-negative bacteria being increasingly reported. Inadequate permeation of anti-infectives into or across the Gram-negative bacterial cell envelope, due to its intrinsic barrier function as well as barrier enhancement mediated by resistance mechanisms, can be identified as one of the major reasons for insufficient therapeutic effects. Several in vitro, in silico, and in cellulo models are currently employed to increase the knowledge of anti-infective transport processes into or across the bacterial cell envelope; however, all such models exhibit drawbacks or have limitations with respect to the information they are able to provide. Thus, new approaches which allow for more comprehensive characterization of anti-infective permeation processes (and as such, would be usable as screening methods in early drug discovery and development) are desperately needed. Furthermore, delivery methods or technologies capable of enhancing anti-infective permeation into or across the bacterial cell envelope are required. In this respect, particle-based carrier systems have already been shown to provide the opportunity to overcome compound-related difficulties and allow for targeted delivery. In addition, formulations combining efflux pump inhibitors or antimicrobial peptides with anti-infectives show promise in the restoration of antibiotic activity in resistant bacterial strains. Despite considerable progress in this field however, the design of carriers to specifically enhance transport across the bacterial envelope or to target difficult-to-treat (e.g., intracellular) infections remains an urgently needed area of improvement. What follows is a summary and evaluation of the state of the art of both bacterial permeation models and advanced anti-infective formulation strategies, together with an outlook for future directions in these fields.

Keywords

Outer Membrane Cell Envelope Envelope Structure Permeation Process Efflux Pump Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Berglund NA, Piggot TJ, Jefferies D, Sessions RB, Bond PJ, Khalid S (2015) Interaction of the antimicrobial peptide polymyxin B1 with both membranes of E. coli: a molecular dynamics study. PLoS Comput Biol 11:1004180CrossRefGoogle Scholar
  2. Cai H, Rose K, Liang LH, Dunham S, Stover C (2009) Development of a liquid chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas aeruginosa. Anal Biochem 385:321–325CrossRefPubMedGoogle Scholar
  3. Chakraborty SP, Sahu SK, Pramanik P, Roy S (2012) In vitro antimicrobial activity of nanoconjugated vancomycin against drug resistant Staphylococcus aureus. Int J Pharm 436:659–676CrossRefPubMedGoogle Scholar
  4. Charitat T, Bellet-Amalric E, Fragneto G, Graner F (1999) Adsorbed and free lipid bilayers at the solid-liquid interface. Eur Phys J B 8:583–593CrossRefGoogle Scholar
  5. Clifton LA, Johnson CL, Solovyova AS, Callow P, Weiss KL, Ridley H, Le Brun AP, Kinane CJ, Webster JR, Holt SA, Lakey JH (2012) Low resolution structure and dynamics of a colicin-receptor complex determined by neutron scattering. J Biol Chem 287:337–346CrossRefPubMedGoogle Scholar
  6. Clifton LA, Skoda MW, Le Brun AP, Ciesielski F, Kuzmenko I, Holt SA, Lakey JH (2015) Effect of divalent cation removal on the structure of gram-negative bacterial outer membrane models. Langmuir 31:404–412CrossRefPubMedGoogle Scholar
  7. Cronin MT, Aptula AO, Dearden JC, Duffy JC, Netzeva TI, Patel H, Rowe PH, Schultz TW, Worth AP, Voutzoulidis K, Schuurmann G (2002) Structure-based classification of antibacterial activity. J Chem Inf Comput Sci 42:869–878CrossRefPubMedGoogle Scholar
  8. Danelon C, Nestorovich EM, Winterhalter M, Ceccarelli M, Bezrukov SM (2006) Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys J 90:1617–1627CrossRefPubMedGoogle Scholar
  9. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, Garnotel E, Molitor A, Pages JM (2008) Membrane permeability and regulation of drug “influx and efflux” in enterobacterial pathogens. Curr Drug Targets 9:750–759CrossRefPubMedGoogle Scholar
  10. Davis TD, Gerry CJ, Tan DS (2014) General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol 9:2535–2544CrossRefPubMedPubMedCentralGoogle Scholar
  11. De E, Basle A, Jaquinod M, Saint N, Mallea M, Molle G, Pages JM (2001) A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol Microbiol 41:189–198CrossRefPubMedGoogle Scholar
  12. Der Wissenschaften Akademie, Hamburg Deutsche Akademie, Leopoldina Der Naturforscher (eds) (2013) Antibiotika-Forschung: Probleme und Perspektiven. De Gruyter, BerlinGoogle Scholar
  13. D’Errico G, Silipo A, Mangiapia G, Molinaro A, Paduano L, Lanzetta R (2009) Mesoscopic and microstructural characterization of liposomes formed by the lipooligosaccharide from Salmonella minnesota strain 595 (Re mutant). Phys Chem Chem Phys 11:2314–2322Google Scholar
  14. Dever LA, Dermody TS (1991) Mechanisms of bacterial resistance to antibiotics. Arch Intern Med 5:886–895Google Scholar
  15. Fernandez DI, Le Brun AP, Whitwell TC, Sani MA, James M, Separovic F (2012) The antimicrobial peptide aurein 1.2 disrupts model membranes via the carpet mechanism. Phys Chem Chem Phys 14:15739–15751CrossRefPubMedGoogle Scholar
  16. Fernandez DI, Le Brun AP, Lee TH, Bansal P, Aguilar MI, James M, Separovic F (2013) Structural effects of the antimicrobial peptide maculatin 1.1 on supported lipid bilayers. Eur Biophys J 42:47–59CrossRefPubMedGoogle Scholar
  17. Fillion P, Desjardins A, Sayasith K, Lagace J (2001) Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides. Biochim Biophys Acta 1515:44–54CrossRefPubMedGoogle Scholar
  18. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science 325:1089–1093CrossRefPubMedPubMedCentralGoogle Scholar
  19. Fragneto G, Charitat T, Daillant J (2012) Floating lipid bilayers: models for physics and biology. Eur Biophys J 41:863–874CrossRefPubMedGoogle Scholar
  20. Gordon YJ, Romanowski EG, McDermott AM (2005) A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 30:505–515CrossRefPubMedPubMedCentralGoogle Scholar
  21. Gornall JL, Mahendran KR, Pambos OJ, Steinbock LJ, Otto O, Chimerel C, Winterhalter M, Keyser UF (2011) Simple reconstitution of protein pores in nano lipid bilayers. Nano Lett 11:3334–3340CrossRefPubMedGoogle Scholar
  22. Hajjar E, Mahendran KR, Kumar A, Bessonov A, Petrescu M, Weingart H, Ruggerone P, Winterhalter M, Ceccarelli M (2010) Bridging timescales and length scales: from macroscopic flux to the molecular mechanism of antibiotic diffusion through porins. Biophys J 98:569–575CrossRefPubMedPubMedCentralGoogle Scholar
  23. Hancock RE (1997) Peptide antibiotics. Lancet 349:418–422CrossRefPubMedGoogle Scholar
  24. Hancock RE, Chapple DS (1999) Peptide antibiotics. Antimicrob Agents Chemother 43:1317–1323PubMedPubMedCentralGoogle Scholar
  25. Huh AJ, Kwon YJ (2011) Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156:128–145CrossRefPubMedGoogle Scholar
  26. Kascakova S, Maigre L, Chevalier J, Refregiers M, Pages JM (2012) Antibiotic transport in resistant bacteria: synchrotron UV fluorescence microscopy to determine antibiotic accumulation with single cell resolution. PLoS ONE 7:e38624CrossRefPubMedPubMedCentralGoogle Scholar
  27. Kreir M, Farre C, Beckler M, George M, Fertig N (2008) Rapid screening of membrane protein activity: electrophysiological analysis of OmpF reconstituted in proteoliposomes. Lab Chip 8:587–595CrossRefPubMedGoogle Scholar
  28. Kubiak J, Brewer J, Hansen S, Bagatolli LA (2011) Lipid lateral organization on giant unilamellar vesicles containing lipopolysaccharides. Biophys J 100:978–986CrossRefPubMedPubMedCentralGoogle Scholar
  29. Kumar A, Schweizer HP (2005) Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57:1486–1513CrossRefPubMedGoogle Scholar
  30. Kuzmenko AI, Wu H, McCormack FX (2006) Pulmonary collectins selectively permeabilize model bacterial membranes containing rough lipopolysaccharide. Biochemistry 45:2679–2685CrossRefPubMedPubMedCentralGoogle Scholar
  31. Le Brun AP, Clifton LA, Halbert CE, Lin B, Meron M, Holden PJ, Lakey JH, Holt SA (2013) Structural characterization of a model gram-negative bacterial surface using lipopolysaccharides from rough strains of Escherichia coli. Biomacromolecules 14:2014–2022CrossRefPubMedPubMedCentralGoogle Scholar
  32. Lemmin T, Bovigny C, Lançon D, Dal Peraro M (2013) Cardiolipin models for molecular simulations of bacterial and mitochondrial membranes. J Chem Theory Comput 9:670–678CrossRefPubMedGoogle Scholar
  33. Lins RD, Straatsma TP (2001) Computer simulation of the rough lipopolysaccharide membrane of Pseudomonas aeruginosa. Biophys J 81:1037–1046CrossRefPubMedPubMedCentralGoogle Scholar
  34. Luckey M, Nikaido H (1980) Specificity of diffusion channels produced by lambda phage receptor protein of Escherichia coli. Proc Natl Acad Sci U S A 77:167–171CrossRefPubMedPubMedCentralGoogle Scholar
  35. Mach T, Chimerel C, Fritz J, Fertig N, Winterhalter M, Futterer C (2008a) Miniaturized planar lipid bilayer: increased stability, low electric noise and fast fluid perfusion. Anal Bioanal Chem 390:841–846CrossRefPubMedGoogle Scholar
  36. Mach T, Neves P, Spiga E, Weingart H, Winterhalter M, Ruggerone P, Ceccarelli M, Gameiro P (2008b) Facilitated permeation of antibiotics across membrane channels-interaction of the quinolone moxifloxacin with the OmpF channel. J Am Chem Soc 130:13301–13309CrossRefPubMedGoogle Scholar
  37. Mahendran KR, Hajjar E, Mach T, Lovelle M, Kumar A, Sousa I, Spiga E, Weingart H, Gameiro P, Winterhalter M, Ceccarelli M (2010) Molecular basis of enrofloxacin translocation through OmpF, an outer membrane channel of Escherichia coli-when binding does not imply translocation. J Phys Chem B 114:5170–5179CrossRefPubMedGoogle Scholar
  38. Mataraci E, Dosler S (2012) In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 56:6366–6371CrossRefPubMedPubMedCentralGoogle Scholar
  39. Mayers D (ed) (2009) Antimicrobial drug resistance: mechanisms of drug resistance. Springer, BerlinGoogle Scholar
  40. McKenna M (2013) The last resort. Nature 499:394–396CrossRefPubMedGoogle Scholar
  41. Meng J, Wang H, Hou Z, Chen T, Fu J, Ma X, He G, Xue X, Jia M, Luo X (2009) Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA. Antimicrob Agents Chemother 53:2871–2878CrossRefPubMedPubMedCentralGoogle Scholar
  42. Miller MB, Bassler BL (2001) Quorum sensing in bacteria. Annu Rev Microbiol 55:165–199CrossRefPubMedGoogle Scholar
  43. Modi N, Winterhalter M, Kleinekathofer U (2012) Computational modeling of ion transport through nanopores. Nanoscale 4:6166–6180CrossRefPubMedGoogle Scholar
  44. Mullineaux CW, Nenninger A, Ray N, Robinson C (2006) Diffusion of green fluorescent protein in three cell environments in Escherichia coli. J Bacteriol 188:3442–3448CrossRefPubMedPubMedCentralGoogle Scholar
  45. Murcia-Soler M, Perez-Gimenez F, Garcia-March FJ, Salabert-Salvador MT, Diaz-Villanueva W, Medina-Casamayor P (2003) Discrimination and selection of new potential antibacterial compounds using simple topological descriptors. J Mol Graph Model 21:375–390CrossRefPubMedGoogle Scholar
  46. Murcia-Soler M, Perez-Gimenez F, Garcia-March FJ, Salabert-Salvador MT, Diaz-Villanueva W, Castro-Bleda MJ, Villanueva-Pareja A (2004) Artificial neural networks and linear discriminant analysis: a valuable combination in the selection of new antibacterial compounds. J Chem Inf Comput Sci 44:1031–1041CrossRefPubMedGoogle Scholar
  47. Murzyn K, Rog T, Pasenkiewicz-Gierula M (2005) Phosphatidylethanolamine-phosphatidylglycerol bilayer as a model of the inner bacterial membrane. Biophys J 88:1091–1103CrossRefPubMedGoogle Scholar
  48. Nafee N, Husari A, Maurer CK, Lu C, De Rossi C, Steinbach A, Hartmann RW, Lehr CM, Schneider M (2014) Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J Control Release 192:131–140CrossRefPubMedGoogle Scholar
  49. Naghmouchi K, Le Lay C, Baah J, Drider D (2012) Antibiotic and antimicrobial peptide combinations: synergistic inhibition of Pseudomonas fluorescens and antibiotic-resistant variants. Res Microbiol 163:101–108CrossRefPubMedGoogle Scholar
  50. Nelson ML, Grier MC, Barbaro SE, Ismail MY (2009) Polyfunctional antibiotics affecting bacterial membrane dynamics. Anti-Infect Agents Med Chem 8:3–16CrossRefGoogle Scholar
  51. Nestorovich EM, Danelon C, Winterhalter M, Bezrukov SM (2002) Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores. Proc Natl Acad Sci U S A 99:9789–9794CrossRefPubMedPubMedCentralGoogle Scholar
  52. Nikaido H, Rosenberg EY (1981) Effect on solute size on diffusion rates through the transmembrane pores of the outer membrane of Escherichia coli. J Gen Physiol 77:121–135CrossRefPubMedGoogle Scholar
  53. Nikaido H, Rosenberg EY (1983) Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J Bacteriol 153:241–252PubMedPubMedCentralGoogle Scholar
  54. Nuding S, Frasch T, Schaller M, Stange EF, Zabel LT (2014) Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile. Antimicrob Agents Chemother 58:5719–5725CrossRefPubMedPubMedCentralGoogle Scholar
  55. O’Shea R, Moser HE (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51:2871–2878CrossRefPubMedGoogle Scholar
  56. Pages JM, Amaral L (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 1794:826–833CrossRefPubMedGoogle Scholar
  57. Pages JM, James CE, Winterhalter M (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6:893–903CrossRefPubMedGoogle Scholar
  58. Pages JM, Kascakova S, Maigre L, Allam A, Alimi M, Chevalier J, Galardon E, Refregiers M, Artaud I (2013) New peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging. ACS Med Chem Lett 4:556–559CrossRefPubMedPubMedCentralGoogle Scholar
  59. Palusinska-Szysz M, Zdybicka-Barabas A, Pawlikowska-Pawlega B, Mak P, Cytrynska M (2012) Anti-Legionella dumoffii activity of Galleria mellonella defensin and apolipophorin III. Int J Mol Sci 13:17048–17064CrossRefPubMedPubMedCentralGoogle Scholar
  60. Pandit KR, Klauda JB (2012) Membrane models of E. coli containing cyclic moieties in the aliphatic lipid chain. Biochim Biophys Acta 1818:1205–1210CrossRefPubMedGoogle Scholar
  61. Park SC, Park Y, Hahm KS (2011) The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci 12:5971–5992CrossRefPubMedPubMedCentralGoogle Scholar
  62. Peetla C, Stine A, Labhasetwar V (2009) Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharma 6:1264–1276CrossRefGoogle Scholar
  63. Piggot TJ, Holdbrook DA, Khalid S (2011) Electroporation of the E. coli and S. aureus membranes: molecular dynamics simulations of complex bacterial membranes. J Phys Chem B 115:13381–13388CrossRefPubMedGoogle Scholar
  64. Pornpattananangkul D, Zhang L, Olson S, Aryal S, Obonyo M, Vecchio K, Huang CM, Zhang L (2011) Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc 133:4132–4139CrossRefPubMedPubMedCentralGoogle Scholar
  65. Renau TE, Leger R, Yen R, She MW, Flamme EM, Sangalang J, Gannon CL, Chamberland S, Lomovskaya O, Lee VJ (2002) Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 12:763–766CrossRefPubMedGoogle Scholar
  66. Ries O, Carnarius C, Steinem C, Ducho C (2015) Membrane-interacting properties of the functionalised fatty acid moiety of muraymycin antibiotics. Med Chem Comm 6:879–886CrossRefGoogle Scholar
  67. Rodrigues C, Gameiro P, Prieto M, De Castro B (2003) Interaction of rifampicin and isoniazid with large unilamellar liposomes: spectroscopic location studies. Biochim Biophys Acta 1620:151–159CrossRefPubMedGoogle Scholar
  68. Silhavy TJ, Kahne D, Walker S (2010) The bacterial cell envelope. Cold Spring Harb Perspect Biol 2:a000414CrossRefPubMedPubMedCentralGoogle Scholar
  69. Singh PR, Ceccarelli M, Lovelle M, Winterhalter M, Mahendran KR (2012) Antibiotic permeation across the OmpF channel: modulation of the affinity site in the presence of magnesium. J Phys Chem B 116:4433–4438CrossRefPubMedGoogle Scholar
  70. Tenover FC (2006) Mechanisms of antimicrobial resistance in bacteria. Am J Med 119:S3–10CrossRefPubMedGoogle Scholar
  71. Van Bambeke F, Pages LM, Lee VJ (2010) Inhibitors of bacterial efflux pumps as adjuvants in antibacterial therapy and diagnostoc tools for detection of resistance by efflux. In: Atta-ur-Rahman Choudary MI (ed) Frontiers in anti-infective drug discovery. Bentham, SharjahGoogle Scholar
  72. Walsh TJ, Yeldandi V, Mcevoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W (1998) Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–2398Google Scholar
  73. Wang L, Chen YP, Miller KP, Cash BM, Jones S, Glenn S, Benicewicz BC, Decho AW (2014) Functionalised nanoparticles complexed with antibiotic efficiently kill MRSA and other bacteria. Chem Commun (Camb) 50:12030–12033CrossRefGoogle Scholar
  74. Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, Johnson-Rollings AS, Jones DL, Lee NM, Otten W, Thomas CM, Williams AP (2013) The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis 13:155–165CrossRefPubMedGoogle Scholar
  75. Wu EL, Fleming PJ, Yeom MS, Widmalm G, Klauda JB, Fleming KG, Im W (2014) E. coli outer membrane and interactions with OmpLA. Biophys J 106:2493–2502CrossRefPubMedPubMedCentralGoogle Scholar
  76. Xiong MH, Bao Y, Yang XZ, Wang YC, Sun B, Wang J (2012) Lipase-sensitive polymeric triple-layered nanogel for “on-demand” drug delivery. J Am Chem Soc 134:4355–4362CrossRefPubMedGoogle Scholar
  77. Xiong MH, Bao Y, Yang XZ, Zhu YH, Wang J (2014) Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev 78:63–76CrossRefPubMedGoogle Scholar
  78. Yount NY, Yeaman MR (2004) Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci U S A 101:7363–7368CrossRefPubMedPubMedCentralGoogle Scholar
  79. Zhao W, Rog T, Gurtovenko AA, Vattulainen I, Karttunen M (2008) Role of phosphatidylglycerols in the stability of bacterial membranes. Biochimie 90:930–938CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  • Florian Graef
    • 1
  • Sarah Gordon
    • 1
  • Claus-Michael Lehr
    • 1
    • 2
  1. 1.Department of Drug DeliveryHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI)SaarbrückenGermany
  2. 2.Department of PharmacySaarland UniversitySaarbrückenGermany

Personalised recommendations